Cogent Biosciences, Inc. (COGT)
NASDAQ: COGT · Real-Time Price · USD
34.54
+0.87 (2.58%)
At close: Jun 18, 2026, 4:00 PM EDT
34.40
-0.14 (-0.41%)
After-hours: Jun 18, 2026, 7:49 PM EDT
Cogent Biosciences Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
258
Market Cap
5.90B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | 7.87M | -14.63M | -65.02% |
| Dec 31, 2019 | 22.50M | 12.77M | 131.14% |
| Dec 31, 2018 | 9.73M | 1.37M | 16.44% |
| Dec 31, 2017 | 8.36M | 2.01M | 31.55% |
| Dec 31, 2016 | 6.36M | 3.37M | 112.83% |
| Dec 31, 2015 | 2.99M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Legend Biotech | 1.14B |
| Caris Life Sciences | 907.29M |
| PTC Therapeutics | 827.11M |
| Mirum Pharmaceuticals | 569.61M |
| Ligand Pharmaceuticals | 274.48M |
| Centessa Pharmaceuticals | 15.00M |
| Xenon Pharmaceuticals | 7.50M |
| CG Oncology | 5.07M |
COGT News
- 7 days ago - Cogent Biosciences Announces Preclinical Data from Novel JAK2 V617F Inhibitor at the 2026 European Hematology Association (EHA) Congress - GlobeNewsWire
- 7 days ago - Cogent Biosciences Announces Detailed Data from APEX Pivotal Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis at the 2026 European Hematology Association (EHA) Congress - GlobeNewsWire
- 10 days ago - Cogent Biosciences Transcript: AGM 2026 - Transcripts
- 16 days ago - Cogent Biosciences Transcript: Jefferies Global Healthcare Conference 2026 - Transcripts
- 19 days ago - Cogent Biosciences announces data from analysis of PEAK Phase 3 trial - TheFly
- 20 days ago - Cogent Biosciences Announces Detailed Clinical Data from PEAK Phase 3 Trial with Bezuclastinib in Combination with Sunitinib in Gastrointestinal Stromal Tumors (GIST) at 2026 American Society of Clinical Oncology (ASCO) Annual Meeting - GlobeNewsWire
- 22 days ago - Cogent Biosciences announces FDA acceptance of bezuclastinib NDA - TheFly
- 22 days ago - Cogent Biosciences Announces FDA Acceptance of New Drug Application (NDA) with Priority Review for Bezuclastinib in Combination with Sunitinib for Patients with GIST - GlobeNewsWire